Clinical trial
A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus
NCT02682563 is registered in ClinicalTrials.gov with M.H.H. Kramer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus
- Lead sponsor
- M.H.H. Kramer
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 29, 2016
- Completion date
- September 30, 2018
- Enrollment
- 44 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.